AR054258A1 - Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa - Google Patents

Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Info

Publication number
AR054258A1
AR054258A1 AR20060101616A ARP060101616A AR054258A1 AR 054258 A1 AR054258 A1 AR 054258A1 AR 20060101616 A AR20060101616 A AR 20060101616A AR P060101616 A ARP060101616 A AR P060101616A AR 054258 A1 AR054258 A1 AR 054258A1
Authority
AR
Argentina
Prior art keywords
phenyl
acceptable salt
aromatase inhibitor
prodrug
patient
Prior art date
Application number
AR20060101616A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR054258A1 publication Critical patent/AR054258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AR20060101616A 2005-04-25 2006-04-24 Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa AR054258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
AR054258A1 true AR054258A1 (es) 2007-06-13

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101616A AR054258A1 (es) 2005-04-25 2006-04-24 Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Country Status (6)

Country Link
EP (1) EP1937251A2 (fr)
JP (1) JP2006306872A (fr)
AR (1) AR054258A1 (fr)
CA (1) CA2605796A1 (fr)
TW (1) TW200716094A (fr)
WO (1) WO2006114702A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
EP2070943A1 (fr) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Procédé de préparation des 6-Alkylidenandrost-1,4-dien-3-ones
JP5777163B2 (ja) * 2009-07-03 2015-09-09 国立研究開発法人理化学研究所 Ｐｅｔ用標識化合物
BR112014005434B1 (pt) * 2011-09-08 2021-01-05 Novartis Ag Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação
EP4029950A1 (fr) * 2016-04-29 2022-07-20 Board of Regents, The University of Texas System Mesure ciblée de l'activité transcriptionnelle liée aux récepteurs hormonaux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AU8986501A (en) * 2000-09-08 2002-03-22 Pharmacia & Upjohn Spa Exemestane as chemopreventing agent
WO2003017974A1 (fr) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Methode de traitement des troubles gynecologiques benins et trousse pharmaceutique destinee a etre utilisee dans ladite methode
IL161162A0 (en) * 2001-10-10 2004-08-31 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
AU2005206137A1 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
RU2007114111A (ru) * 2004-11-04 2008-12-10 Пфайзер Продактс Инк. (Us) Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы

Also Published As

Publication number Publication date
WO2006114702A2 (fr) 2006-11-02
TW200716094A (en) 2007-05-01
EP1937251A2 (fr) 2008-07-02
WO2006114702A3 (fr) 2007-01-04
CA2605796A1 (fr) 2006-11-02
JP2006306872A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
AU2006272652B2 (en) 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
AR054258A1 (es) Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa
CA2983927A1 (fr) Modulateurs de k-ras
JP2009536667A (ja) ５ｈｔ受容体介在性の神経新生
JP2015500887A5 (fr)
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CO5670328A2 (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
JP2016516043A5 (fr)
JP2010500993A (ja) Ｈｓｐ９０活性を調節するトリアゾール化合物
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MXPA04002037A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
MX2023001468A (es) Tratamiento de cancer de prostata.
JP2010503674A (ja) 血管形成治療用化合物
DE60322680D1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
RU2004104329A (ru) Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
EA201000656A1 (ru) Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
RU2006108557A (ru) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
MX2016009226A (es) Combinaciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal